• Adjunct Professor, Global Health
  • Professor, Medicine - Allergy and Infectious Dis.
  • Adjunct Professor, Microbiology

CERID
750 Republican Street, E606
University of Washington Box 358061
Seattle, WA 98109
United States

Phone Number: 
206-543-2447
Email: 
wesley@uw.edu
Select from the following:
Biography 

Wes trained at MIT (undergraduate), Cornell Medical College and Rockefeller University for MD/PhD degrees, UC San Francisco for internal medicine and University of Washington (UW) for ID Fellowship. As a UW faculty member, Wes researches, practices medicine, teaches, and until 2017, led the Division of Allergy and Infectious Diseases at UW. Wes is the Director of the Center for Emerging and Re-emerging Infectious Diseases, which takes a multidisciplinary approach to identifying and developing diagnostic, therapeutic and vaccine solutions to emerging IDs. For the past 25 years, Wes works on pre-clinical drug development for malaria, trypanosomes, leishmania, and cryptosporidium. He works extensively in target-based drug development and, where possible, uses iterative structure-based drug development. Wes’ lab is now characterizing a new preclinical drug candidate for the treatment of cryptosporidiosis. He is also the PI of a clinical trial to test the efficacy of clofazimine for cryptosporidiosis in Malawi.

Education 
  • MD (Cornell University)
  • PhD (Rockefeller University)
  • BS (Massachusetts Institute of Technology)
Country Affiliations 
Languages 
  • Spanish
Health Topics 
  • Infectious Diseases
  • Infectious Diseases (other than STDs)
  • Leishmaniasis
  • Malaria
  • Pathobiology
  • STDs (other than HIV)
  • TB
Pathobiology research areas 
Publications 

Hulverson MA, Vinayak S, Choi R, Schaefer DA, Castellanos-Gonzalez A, Vidadala RSR, Brooks CF, Herbert GT, Betzer DP, Whitman GR, Sparks HN, Arnold SLM, Rivas KL, Barrett LK, White AC Jr, Maly DJ, Riggs MW, Striepen B, Van Voorhis WC, Ojo KK. Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy. J Infect Dis. 2017 Apr 15;215(8):1275-1284.

Phillips MA, Burrows JN, Manyando C, van Huijsduijnen RH, Van Voorhis WC, Wells TNC. Malaria. Nat Rev Dis Primers. 2017 Aug 3;3:17050. doi: 10.1038/nrdp.2017.50. PubMed PMID: 28770814 {Review}

Lee S, Ginese M, Beamer G, Danz HR, Girouard DJ, Chapman-Bonofiglio SP, Lee M, Hulverson MA, Choi R, Whitman GR, Ojo KK, Arnold SLM, Van Voorhis WC, Tzipori S. Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in the Acute Pig Model of Cryptosporidium hominis. Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00147-18. doi: 10.1128/AAC.00147-18. [Epub ahead of print] PubMed PMID: 29661877. {Original Research}

Vu H, Pedro L, Mak T, McCormick B, Rowley J, Liu M, Di Capua A, Williams-Noonan B, Pham NB, Pouwer RH, Nguyen B, Andrews KT, Skinner-Adams T, Kim J, Hol WGJ, Hui R, Crowther GJ, Van Voorhis WC, Quinn RJ. Fragment-Based Screening of a Natural Product Library against 62 Potential Malaria Drug Targets Employing Native Mass Spectrometry. ACS Infect Dis. 2018 Feb 13. doi:10.1021/acsinfecdis.7b00197. [Epub ahead of print] PubMed PMID: 29436819. {Original Research}

Müller J, Aguado-Martínez A, Ortega-Mora LM, Moreno-Gonzalo J, Ferre I, Hulverson MA, Choi R, McCloskey MC, Barrett LK, Maly DJ, Ojo KK, Van Voorhis W, Hemphill A. Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis. J Antimicrob Chemother. 2017 Aug 1;72(8):2334-2341. doi: 10.1093/jac/dkx134. PubMed PMID: 28486633. {Original Research}